Xie W, Yang X, Huang H, et al. - Researchers investigated if and how exposure to non-tumor necrosis factor-α inhibitor (TNFi) biologics or tofacitinib therapy is related to the risk of developing cancer in patients suffering from rheumatoid arthritis (RA). PubMed, EMBASE and Cochrane Library were explored in addition to conference proceedings, to identify eligible studies: observational studies evaluating cancer incidence in RA patients managed with biologics or tofacitinib with active comparator of conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs) or TNFi. Overall 10 studies were analyzed. Findings revealed abatacept exposure in RA patients was associated with a small statistically significant increase in developing cancer while exposure to rituximab, tocilizumab or tofacitinib did not increase cancer risk in RA patients, compared with csDMARDs or TNFi.